Earnings Call Summary | ICU Medical(ICUI.US) Q4 2023 Earnings Conference
Earnings Call Summary | ICU Medical(ICUI.US) Q4 2023 Earnings Conference
The following is a summary of the ICU Medical, Inc. (ICUI) Q4 2023 Earnings Call Transcript:
以下是ICU Medical, Inc.（ICUI）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
ICU Medical's full year 2023 consolidated adjusted revenue was down 1% in reported terms and flat in constant currency.
The company's Q4 gross margin was 34%, reflecting the impact from lower manufacturing absorption.
Q4 adjusted diluted earnings per share was $1.57 compared to $1.60 last year.
Q4 adjusted EBITDA decreased by 11%.
For 2024, the company expects full year consolidated adjusted revenue growth in the mid-single-digit range.
ICU Medical2023年全年合併調整後收入按報告計算下降了1％，按固定貨幣計算持平。
該公司第四季度的毛利率爲34％，反映了製造業吸收率下降的影響。
第四季度調整後的攤薄後每股收益爲1.57美元，而去年同期爲1.60美元。
第四季度調整後的息稅折舊攤銷前利潤下降了11％。
該公司預計，2024年的全年合併調整後收入增長將在個位數中位數區間內。
Business Progress:
業務進展：
The company has invested in quality system and product-related remediation for legacy SM.
ICU Medical plans to further reduce inventory during 2024.
All product lines in the Consumables segment reported sequential growth due to new global customer implementations and improved capacity.
The company's newly cleared Plum Duo infusion system and LifeShield IV safety software are production ready.
Future development is focused on a single-channel infusion system and a refreshed syringe pump.
The company is prioritizing debt repayment as the highest capital allocation priority.
該公司已對傳統SM的質量體系和產品相關補救措施進行了投資。
重症監護病房醫療計劃在2024年進一步減少庫存。
由於全球新客戶的實施和產能的提高，消費品板塊的所有產品線均報告了連續增長。
該公司新批准的Plum Duo輸液系統和LifeShield IV安全軟件已準備就緒。
未來的開發重點是單通道輸液系統和更新的注射器泵。
該公司將償還債務作爲最高資本配置優先事項。
More details: ICU Medical IR
更多詳情： 重症監護病房醫療紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。